Lecanemab's benefits are too small and uncertain

BMJ. 2024 Sep 19:386:q2044. doi: 10.1136/bmj.q2044.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Humans

Substances

  • lecanemab
  • Antibodies, Monoclonal, Humanized